| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5552394 | TEVA BRANDED PHARM | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(9 years ago) | |
| US6667050 | TEVA BRANDED PHARM | Chewable oral contraceptive |
Apr, 2019
(5 years ago) | |
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate is owned by Teva Branded Pharm.
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate contains Ethinyl Estradiol; Norethindrone.
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Norethindrone And Ethinyl Estradiol And Ferrous Fumarate are:
- US5552394
- US6667050
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate was authorised for market use on 22 December, 2010.
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate is available in tablet, chewable;oral dosage forms.
Norethindrone And Ethinyl Estradiol And Ferrous Fumarate can be used as prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
The generics of Norethindrone And Ethinyl Estradiol And Ferrous Fumarate are possible to be released after 06 April, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 22, 2013 |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ingredient
Market Authorisation Date: 22 December, 2010
Treatment: Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
Dosage: TABLET, CHEWABLE;ORAL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE family patents
